Lipocines Breakthrough Bioequivalence Study Results Pave the Way for Revolutionary Pharmacological Treatment
Lipocine Inc., a renowned biopharmaceutical company, has recently announced groundbreaking results from various studies, demonstrating the bioequivalence of its oral drug candidate, LPCN 1154, to the intravenous (IV) fo...
Jul 22, 2024
• Major Pharmaceutical Preparations Industry
Stocks on the Move
Lipocine Inc The The U
